Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 21Prostatic Neoplasms 17Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Neoplasms 7Neoplasm Metastasis 6Carcinoma, Transitional Cell 5Triple Negative Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3Melanoma 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma 3Recurrence 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2HER2-positive Breast Cancer 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2

Interventions

enzalutamide 1Gemcitabine 1Docetaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Fibromatosis, Gingival, 2 × Docetaxel × Clear all
NCT05919537 2025-04-18

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Hummingbird Bioscience

Phase 1 Active not recruiting
68 enrolled
GastrointestinalThoracic

Fibromatosis, Gingival, 2, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡